KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Interest Expenses (2016 - 2020)

Nektar Therapeutics (NKTR) has 11 years of Interest Expenses data on record, last reported at $647000.0 in Q2 2020.

  • For Q2 2020, Interest Expenses fell 87.63% year-over-year to $647000.0; the TTM value through Mar 2021 reached $647000.0, down 97.1%, while the annual FY2020 figure was $6.9 million, 67.85% down from the prior year.
  • Interest Expenses reached $647000.0 in Q2 2020 per NKTR's latest filing, down from $6.2 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $6.2 million in Q1 2020 and bottomed at $647000.0 in Q2 2020.
  • Average Interest Expenses over 5 years is $5.2 million, with a median of $5.4 million recorded in 2018.
  • Peak YoY movement for Interest Expenses: skyrocketed 36.64% in 2016, then tumbled 87.63% in 2020.
  • A 5-year view of Interest Expenses shows it stood at $5.6 million in 2016, then grew by 1.5% to $5.6 million in 2017, then decreased by 3.87% to $5.4 million in 2018, then rose by 0.24% to $5.4 million in 2019, then plummeted by 88.08% to $647000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $647000.0 in Q2 2020, $6.2 million in Q1 2020, and $5.4 million in Q4 2019.